Opicapone Patent Expiration

Opicapone is Used for treating Parkinson's disease by providing adjunctive therapy to patients experiencing off episodes in combination with levodopa/carbidopa. It was first introduced by Amneal Pharmaceuticals Llc in its drug Ongentys on Apr 24, 2020.


Opicapone Patents

Given below is the list of patents protecting Opicapone, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Ongentys US10071085 Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof Mar 31, 2030 Amneal
Ongentys US10357468 Medicaments for slowing Parkinson's disease May 27, 2035 Amneal
Ongentys US10583130 Pharmaceutical formulations compromising nitrocatechol derivatives and methods of making thereof Mar 31, 2030 Amneal
Ongentys US8168793 Nitrocatechol derivatives as COMT inhibitors Apr 02, 2029 Amneal
Ongentys US8524746 Dosage regimen for COMT inhibitors Jul 14, 2029 Amneal
Ongentys US8907099 Nitrocatechol derivatives as COMT inhibitors May 12, 2027 Amneal
Ongentys US9550759 Nitrocatechol derivatives as COMT inhibitors Jul 26, 2026 Amneal
Ongentys US9630955 Chemical compound useful as intermediate for preparing a catechol-O-methyltransferase inhibitor Dec 12, 2032 Amneal
Ongentys US9745290 Dosage regimen for COMT inhibitors Oct 10, 2027 Amneal


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳